JP2023536667A5 - - Google Patents

Info

Publication number
JP2023536667A5
JP2023536667A5 JP2023507979A JP2023507979A JP2023536667A5 JP 2023536667 A5 JP2023536667 A5 JP 2023536667A5 JP 2023507979 A JP2023507979 A JP 2023507979A JP 2023507979 A JP2023507979 A JP 2023507979A JP 2023536667 A5 JP2023536667 A5 JP 2023536667A5
Authority
JP
Japan
Prior art keywords
tablet formulation
formulation according
approximately
weight
tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023507979A
Other languages
English (en)
Japanese (ja)
Other versions
JP7827696B2 (ja
JP2023536667A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/044295 external-priority patent/WO2022031666A1/en
Publication of JP2023536667A publication Critical patent/JP2023536667A/ja
Publication of JP2023536667A5 publication Critical patent/JP2023536667A5/ja
Priority to JP2026029931A priority Critical patent/JP2026086851A/ja
Application granted granted Critical
Publication of JP7827696B2 publication Critical patent/JP7827696B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023507979A 2020-08-04 2021-08-03 トリフェニルカルシリティック化合物の製剤 Active JP7827696B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026029931A JP2026086851A (ja) 2020-08-04 2026-02-26 トリフェニルカルシリティック化合物の製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063061050P 2020-08-04 2020-08-04
US63/061,050 2020-08-04
PCT/US2021/044295 WO2022031666A1 (en) 2020-08-04 2021-08-03 Formulations of triphenyl calcilytic compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026029931A Division JP2026086851A (ja) 2020-08-04 2026-02-26 トリフェニルカルシリティック化合物の製剤

Publications (3)

Publication Number Publication Date
JP2023536667A JP2023536667A (ja) 2023-08-28
JP2023536667A5 true JP2023536667A5 (enExample) 2024-08-13
JP7827696B2 JP7827696B2 (ja) 2026-03-10

Family

ID=77431430

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023507979A Active JP7827696B2 (ja) 2020-08-04 2021-08-03 トリフェニルカルシリティック化合物の製剤
JP2026029931A Pending JP2026086851A (ja) 2020-08-04 2026-02-26 トリフェニルカルシリティック化合物の製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026029931A Pending JP2026086851A (ja) 2020-08-04 2026-02-26 トリフェニルカルシリティック化合物の製剤

Country Status (13)

Country Link
US (2) US20220040112A1 (enExample)
EP (1) EP4192438A1 (enExample)
JP (2) JP7827696B2 (enExample)
KR (1) KR20230106582A (enExample)
CN (1) CN116648243A (enExample)
AR (1) AR123147A1 (enExample)
AU (1) AU2021320147B2 (enExample)
BR (1) BR112023002107A2 (enExample)
CA (1) CA3188044A1 (enExample)
IL (1) IL300285A (enExample)
MX (1) MX2023001438A (enExample)
TW (1) TWI924683B (enExample)
WO (1) WO2022031666A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116648243A (zh) 2020-08-04 2023-08-25 柯西立提克斯疗法有限公司 三苯基钙敏感化合物的制剂
MX2023003129A (es) * 2020-09-18 2023-08-04 Calcilytix Therapeutics Inc Compuestos trifenil-calciliticos para el tratamiento de hipocalcemia autosomica dominante tipo 1 (adh1).
WO2024160842A1 (en) 2023-01-30 2024-08-08 Medizinische Universität Wien Use of calcilytics for preventing or treating hypoparathyroidism associated with anterior neck surgery

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050460A1 (es) 2003-04-23 2005-07-08 Japan Tobacco Inc COMPUESTOS HETEROCICLICOS COMO ANTAGONISTAS CaSR (RECEPTOR SENSIBLE AL CALCIO)
EP1964548A1 (en) * 2007-03-02 2008-09-03 Novartis AG Pharmaceutical compositions comprising a calcilytic agent
SG174564A1 (en) * 2009-03-26 2011-10-28 Japan Tobacco Inc Process for producing carboxylic acid compound
ES2900353T3 (es) * 2010-04-07 2022-03-16 Vertex Pharma Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas
GB201217330D0 (en) * 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders
BR112020013073A2 (pt) 2017-12-29 2020-12-01 Biomarin Pharmaceutical Inc. composto, composto, estereoisômero único ou mistura de estereoisômeros ou sal farmaceuticamente aceitável, composição farmacêutica, método de tratamento de uma doença ou distúrbio e composto ou sal farmaceuticamente aceitável do mesmo
WO2021029517A1 (en) 2019-08-13 2021-02-18 Dongguk University Industry-Academic Cooperation Foundation Pharmaceutical composition for improving or treating post-surgical hypoparathyroidism and treatment method using the same
GB201918586D0 (en) * 2019-12-17 2020-01-29 Patterson James Engineered platelets for targeted delivery of a therapeutic agent
CN116648243A (zh) 2020-08-04 2023-08-25 柯西立提克斯疗法有限公司 三苯基钙敏感化合物的制剂
MX2023003129A (es) 2020-09-18 2023-08-04 Calcilytix Therapeutics Inc Compuestos trifenil-calciliticos para el tratamiento de hipocalcemia autosomica dominante tipo 1 (adh1).

Similar Documents

Publication Publication Date Title
JP2021512117A5 (enExample)
US20070036850A1 (en) Film-coated tablet or granules containing as active ingredient a pyridylpyrimidine compound or a pharmaceutically acceptable salt of this compound
US20140235558A1 (en) Pharmaceutical composition having activity of anticancer
JP2022542804A5 (enExample)
US11260047B2 (en) Formulations of AG10
US11576917B2 (en) Pharmaceutical compositions comprising Ibrutinib
KR102555956B1 (ko) 안정성이 향상된 라베프라졸을 유효성분으로 포함하는 경구용 속방형 제제 및 이의 제조방법
WO2022225489A1 (en) A bilayer tablet formulation comprising amorphous dapagliflozin and metformin
JP2023548855A5 (enExample)
JP7585043B2 (ja) レナリドミドを含む医薬組成物
US11730753B2 (en) Stable pharmaceutical compositions comprising trifluridine and tipiracil hydrochloride
US20210267908A1 (en) Pharmaceutical compositions of rivaroxaban
EP3318279B1 (en) Solid oral pharmaceutical compositions of lurasidone hydrochloride
JP2024525954A5 (enExample)
JP7355846B2 (ja) 固形製剤
WO2015069203A1 (en) Capsule comprising rupatadine fumarate and montelukast sodium
JP2024503689A5 (enExample)
KR102258372B1 (ko) 베포타스틴의 방출 제어형 경구 제제
US12059419B2 (en) Pharmaceutical composition comprising phthalazinone derivatives
JP7423297B2 (ja) 口腔内崩壊錠およびその製造方法
US10034855B2 (en) Solid composition of pyrrole carboxamide
EP4140478A1 (en) A solid pharmaceutical composition comprising sacubitril and valsartan
WO2023027671A1 (en) A solid pharmaceutical composition comprising sacubitril and valsartan
JP5827428B1 (ja) テルミサルタン含有錠剤
EA045272B1 (ru) Твердая фармацевтическая композиция на основе гидрохлорида луразидона для перорального применения